Menu Search
Equities

DarioHealth Corp

LS1P:BER

DarioHealth Corp

Actions
  • Price (EUR)0.80
  • Today's Change0.02 / 2.56%
  • Shares traded1.03k
  • 1 Year change-13.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year DarioHealth Corp has grown net income from a loss of -62.19m to a smaller loss of -59.43m despite falling revenues.
Gross margin39.90%
Net profit margin-205.62%
Operating margin-278.12%
Return on assets-43.80%
Return on equity-69.90%
Return on investment-50.02%
More ▼

Cash flow in USDView more

In 2023, cash reserves at DarioHealth Corp fell by 12.67m. Cash Flow from Financing totalled 18.25m or 89.69% of revenues. In addition the company used 30.38m for operations while cash used for investing totalled 547.00k.
Cash flow per share-1.17
Price/Cash flow per share--
Book value per share1.87
Tangible book value per share-0.6148
More ▼

Balance sheet in USDView more

DarioHealth Corp has a Debt to Total Capital ratio of 33.03%, a lower figure than the previous year's 42.63%.
Current ratio1.57
Quick ratio1.32
Total debt/total equity0.4932
Total debt/total capital0.3303
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.